Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReLOAD Trial
NCT07071961Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and lorigerlimab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year and 6-month circulating tumor DNA clearance rate. Started Feb 2026; status: recruiting.
02
Drugs
regorafeniblorigerlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07071961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071961.